Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
about
A novel classification of lung cancer into molecular subtypesMass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial.Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC.Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.Mass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerSerum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancer.VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft modelsEmerging molecular biomarkers--blood-based strategies to detect and monitor cancer.The emerging era of personalized therapy in squamous cell carcinoma of the head and neck.Exploring biomarkers in head and neck cancer.Human gene control by vital oncogenes: revisiting a theoretical model and its implications for targeted cancer therapy.Proteomic biomarkers in lung cancer.Emerging tyrosine kinase inhibitors for head and neck cancer.The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.Writing in PROSE proteomic-based selection for second line treatment in non-small-cell lung cancer.Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation.Identification of MXRA5 as a novel biomarker in colorectal cancer.Diagnostic accuracy of MALDI-TOF mass spectrometry for non-small cell lung cancer: a meta-analysis.Serum peptide expression and treatment responses in patients with advanced non-small-cell lung cancer.
P2860
Q28731874-D1B58745-0044-4BFA-8DFB-7E1F8162E263Q33778668-7EB61C75-974F-4375-BC6B-C40D7A9478C0Q33913549-0D214350-989E-4396-9370-A0FB0626786AQ34443983-76D75BB4-77CF-4CA7-A34F-8FF58685C74FQ35034044-183FBAD3-5E23-421A-9ECD-0D5D3B1A8331Q35081379-73373BD4-B769-4C23-B68A-402B261803BFQ35238008-D7EA6449-6808-46BD-BA89-D3A57A110352Q35673572-50723CBF-B75C-4EE9-905F-17EF079E336DQ36109779-CB306415-077C-432D-9F1D-9D3D20B6F4E4Q36293419-4D932A0B-09C8-4D84-82ED-28B6647AF123Q36419366-0C565CED-7E2F-4D25-9047-CD199A5CA53BQ36629392-BC5012AD-45E3-4F8E-8ADA-48950E7D3B1BQ37848663-D7800B38-0F32-42F1-BC8D-43221FC0478AQ37925133-DD86A23C-B4E7-4E86-B49D-B920E34545D1Q37979126-76D6512E-EBF4-4F65-9F74-9C058B8FD369Q37982050-3B0226AA-54CA-47BA-A2DE-B99D986AAD05Q38100750-83BAF86C-8875-47AB-BA54-AF7BE4E17DEDQ38149327-D1196EFF-6819-4F2F-99E8-879254197873Q38768030-6668938C-3425-477E-900A-CFA2AD07F734Q40451221-A5E95092-F84C-4E93-A1C8-457ABA084E17Q41814784-3AE23A93-215B-4D52-BCCE-1AF9D6D9C59FQ42582783-8D3ED6AD-028F-4E42-99FC-1F3835D2BB7FQ43247137-DC51E348-901A-4457-8978-2CDC9B20049BQ49628399-F6CC7AB9-F81A-4CD1-866C-9DDCAC6AFAFFQ54977786-BB0065C7-5B0D-4107-94B4-BD2479EA7124
P2860
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@ast
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@en
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@nl
type
label
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@ast
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@en
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@nl
prefLabel
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@ast
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@en
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@nl
P2093
P2860
P1476
Detection of tumor epidermal g ...... ectrometry in cancer patients.
@en
P2093
Arlene A Forastiere
Athanassios Argiris
Barbara A Burtness
Barbara Murphy
Christine H Chung
David P Carbone
Erin H Seeley
Ezra E W Cohen
Heinrich Roder
Jill Gilbert
P2860
P304
P356
10.1158/1055-9965.EPI-09-0937
P577
2010-01-19T00:00:00Z